Literature DB >> 10893159

The internal rotavirus protein VP6 primes for an enhanced neutralizing antibody response.

F R Esquivel1, S Lopez, L Guitierrez-X, C Arias.   

Abstract

We studied in the rotavirus system whether the internal protein VP6 could prime for an enhancement in the production of neutralizing antibodies (NeuAb) against the external proteins, VP7 and VP4. It was found that BALB/c mice immunized with recombinant YM VP6 protein, and challenged i.p. with a heterologous rotavirus had an increase in the production of serum NeuAb compared to the control. This response was both homotypic and heterotypic, and involved an increase of NeuAb belonging to the IgM and IgG isotypes. Mice immunized with the recombinant VP6 and challenged orally with infectious murine rotavirus cleared the infection one day earlier than the control not immunized with VP6, and showed a small increase of total fecal anti-rotavirus IgA. The results suggest that the T-helper (Th) cells specific for VP6 can provide cognate help to B cells specific for neutralizing epitopes on the VP7 and/or VP4 molecules, and that this help can be heterotypic. Finally, we provide evidence that this phenomenon may be happening during infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893159     DOI: 10.1007/s007050050674

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  11 in total

1.  A new rotavirus VP6-based foreign epitope presenting vector and immunoreactivity of VP4 epitope chimeric proteins.

Authors:  Yumei Teng; Bingxin Zhao; Xiaoxia Pan; Yuling Wen; Yuanding Chen
Journal:  Viral Immunol       Date:  2014-04-04       Impact factor: 2.257

2.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

3.  Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection.

Authors:  Marli S P Azevedo; Lijuan Yuan; Cristiana Iosef; Kyeong-Ok Chang; Yunjeong Kim; Trang Van Nguyen; Linda J Saif
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

4.  CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.

Authors:  Liusong Yin; J Mauricio Calvo-Calle; John Cruz; Frances K Newman; Sharon E Frey; Francis A Ennis; Lawrence J Stern
Journal:  J Immunol       Date:  2013-05-10       Impact factor: 5.422

5.  Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.

Authors:  L Yuan; C Iosef; M S Azevedo; Y Kim; Y Qian; A Geyer; T V Nguyen; K O Chang; L J Saif
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.

Authors:  Suvi Lappalainen; Ana Ruth Pastor; Maria Malm; Vanessa López-Guerrero; Fernando Esquivel-Guadarrama; Laura A Palomares; Timo Vesikari; Vesna Blazevic
Journal:  Arch Virol       Date:  2015-05-29       Impact factor: 2.574

7.  Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.

Authors:  Suvi Lappalainen; Ana Ruth Pastor; Kirsi Tamminen; Vanessa López-Guerrero; Fernando Esquivel-Guadarrama; Laura A Palomares; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.

Authors:  Vesna Blazevic; Maria Malm; Daisuke Arinobu; Suvi Lappalainen; Timo Vesikari
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

9.  Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.

Authors:  M Malm; S Heinimäki; T Vesikari; V Blazevic
Journal:  Clin Exp Immunol       Date:  2017-05-16       Impact factor: 4.330

10.  Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes.

Authors:  Andrea Peralta; Paula Molinari; Oscar Taboga
Journal:  Virol J       Date:  2009-11-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.